Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen’s expertise in developing multispecific molecules.
Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies
February 3, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022